Home Spirometry App Market Report 2026

The home spirometry app market size has grown rapidly in recent years. It will grow from $1.13 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increasing prevalence of chronic respiratory diseases, expansion of home-based healthcare monitoring, rising adoption of connected medical devices, improved accuracy of portable spirometers, growing acceptance of remote patient monitoring.

The home spirometry app market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period can be attributed to increasing demand for chronic disease management tools, rising integration with electronic health records, expansion of ai-assisted respiratory analytics, growing use in post-acute care monitoring, increasing adoption of virtual pulmonary care models. Major trends in the forecast period include increasing adoption of remote lung function monitoring, rising integration with smart spirometry devices, growing use of longitudinal respiratory data analytics, expansion of telehealth-compatible spirometry platforms, enhanced focus on clinical-grade measurement accuracy.

The rising prevalence of respiratory diseases is expected to drive the growth of the home spirometry app market in the coming years. Respiratory diseases are medical conditions that impact the lungs and airways, leading to breathing difficulties and symptoms such as coughing, wheezing, shortness of breath, and chest tightness. The increase in respiratory diseases is attributed to an aging population that is more vulnerable to chronic lung disorders, along with growing exposure to air pollution that negatively affects respiratory health. Home spirometry apps support the management of respiratory conditions by allowing patients to routinely assess lung function from their homes, monitor symptoms over time, identify early signs of deterioration, and share real-time data with healthcare providers for timely clinical intervention. This approach helps maintain better respiratory health and reduces the risk of complications. For example, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, Australia recorded 474 asthma-related deaths in 2023, including 325 females and 149 males. This figure closely mirrors the 473 asthma-related deaths reported in 2022, indicating a consistent pattern in asthma mortality across the two years. As a result, the increasing prevalence of respiratory diseases is contributing to the expansion of the home spirometry app market.

Companies operating in the home spirometry app market are increasingly focusing on developing innovative solutions, such as cardiopulmonary assessment devices, to enable remote monitoring, enhance disease management, and personalize treatment for patients with respiratory conditions. Cardiopulmonary assessment devices allow both patients and clinicians to monitor heart and lung function in real time, facilitating early detection of respiratory issues, individualized treatment modifications, and improved management of chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). For instance, in September 2025, electronRx Ltd., a UK-based deep technology company, introduced its pDx app, a home-based cardiopulmonary assessment platform designed for individuals with chronic respiratory diseases. The application enables users to measure lung function using a smartphone, tablet, or laptop while generating digital biomarkers such as heart rate, respiratory rate, and tidal volume. Healthcare professionals can access real-time patient data through a secure dashboard, supporting remote monitoring, early identification of disease progression, and personalized treatment adjustments. This capability helps reduce the need for frequent hospital visits and improves overall patient outcomes. The platform also incorporates customized questionnaires and provides detailed insights to both patients and clinicians, promoting informed decision-making and greater patient involvement in care.

In May 2025, Huma Therapeutics Limited, a UK-based health technology company, acquired Aluna, Inc. for an undisclosed sum. Through this acquisition, Huma aims to strengthen its respiratory health offerings by integrating Aluna’s AI-enabled remote monitoring solutions and proprietary spirometry devices into the Huma Cloud Platform. This integration is intended to create a comprehensive digital health ecosystem that enhances chronic respiratory care for patients, healthcare providers, and health systems globally. Aluna Inc. is a US-based technology company specializing in home spirometry applications for remote respiratory health monitoring.

Major companies operating in the home spirometry app market are Cipla Limited, Clario Inc., Contec Medical Systems Co. Ltd., Vitalograph Ltd., NDD Medical Technologies AG, CareSimple Inc., MediTuner AB, NuvoAir AB, Monitored Therapeutics Inc., Sibelmed S.A., ZEPHYRx LLC, Alveofit Technologies Pvt. Ltd., Spiromagic ApS, Respirit Healthcare Pvt. Ltd., patientMpower Ltd., CMI Health Inc. (SpiroLink), Smart Respiratory Products Ltd., Koneksa Health Inc., AioCare Sp. z o.o., VitalFlo Inc.

North America was the largest region in the home spirometry app market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the home spirometry app market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the home spirometry app market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the home spirometry app market by increasing costs of imported sensors, medical-grade electronics, and wireless modules used in connected spirometry devices. Healthcare providers in North America and Europe are most affected due to dependence on imported diagnostic hardware, while Asia-Pacific faces higher manufacturing costs for export-oriented devices. These tariffs can raise device prices and slow deployment in home-care settings. However, they are also driving local device assembly, software-centric innovation, and stronger focus on app-based value enhancement.

The home spirometry app market research report is one of a series of new reports that provides home spirometry app market statistics, including home spirometry app industry global market size, regional shares, competitors with a home spirometry app market share, detailed home spirometry app market segments, market trends and opportunities, and any further data you may need to thrive in the home spirometry app industry. This home spirometry app market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A home spirometry app is a digital solution developed to remotely measure and monitor lung function. It connects with spirometry devices to capture detailed respiratory parameters such as forced expiratory volume, forced vital capacity, and peak expiratory flow, delivering accurate insights into lung performance. The app securely records, organizes, and displays respiratory data over time, allowing trends and patterns to be evaluated to support continuous monitoring, early identification of changes, and effective management of pulmonary health.

The main product types of home spirometry apps are standalone apps and integrated apps. A standalone app is a self-contained software application that functions independently on a device without requiring external systems or constant internet connectivity for its primary operations. These apps are compatible with multiple platforms, including iPhone operating system (iOS), Android, Windows, and others, and are distributed through app stores, direct sales, healthcare facilities, and other channels. They are used for a range of applications such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, pulmonary fibrosis, and other respiratory disorders, and are utilized by various end-users including patients, healthcare providers, and research institutes.

The home spirometry app market consists of revenues earned by entities by providing services such as telehealth integration, personalized health coaching, data storage and trend tracking, software development kits (SDKs) medication adherence tracking, patient education and training, clinical trial support, predictive analytics, multi-device connectivity, insurance and reimbursement support, professional dashboards for healthcare providers, and regulatory compliance and data security services. The market value includes the value of related goods sold by the service provider or included within the service offering. The home spirometry app market also includes sales of accessories and supporting tools, digital home spirometers, remote monitoring and telehealth platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.